Effect of highly purified urinary follicle-stimulating hormone on oocyte and embryo quality

Helmy A. Selman, Ph.D.,a,b Mariella De Santo, M.D.,a Karl Sterzik, M.D.,c Elisabetta Coccia, M.D.,d and Imam El-Danasouri, D.V.M., Ph.D.a

Istituto Europeo Medicina della Riproduzione Abruzzese, Spatocco Hospital, Chieti; Probios Reproductive Medicine Clinic, Brindisi; and Policlinico Careggi, Florence University, Florence, Italy; and Institute for Reproductive Medicine, Ulm, Germany

Objective: To determine the effects of ovarian stimulation with highly purified urofollicitropin on oocyte and embryo quality.

Design: Parallel randomized open-label clinical study.

Setting: Assisted reproduction centers.

Patient(s): Two hundred sixty-seven infertile couples undergoing IVF/ICSI.

Intervention(s): All participants underwent standard down-regulation with GnRH analogue. One hundred thirty-three participants received highly purified urinary FSH and 134 controls received recombinant FSH.

Main Outcome Measure(s): Primary end points were number of morphologically mature oocytes retrieved, embryo quality, and pregnancy and implantation rates. Secondary end points were: total number of days of FSH stimulation, total dose of gonadotropin administered, fertilization rate per number of retrieved oocytes, embryo cleavage rate, live birth and miscarriage rates, endometrial thickness and estradiol level on the day of hCG administration, cancellation rate, and incidence of moderate or severe ovarian hyperstimulation syndrome.

Result(s): Pregnancy and implantation rates were nonsignificantly higher in the urinary FSH group than the recombinant FSH group (46.5% vs. 36.8% and 22.1% vs. 15.8%, respectively). The grade 1 embryo score was significantly higher in the urinary FSH group than the recombinant FSH (42.1% vs. 33.5%), and the live birth rate was nonsignificantly higher in the former group.

Conclusion(s): Highly purified urinary FSH is as effective, efficient, and safe for clinical use as recombinant FSH. (Fertil Steril 2002;78:1061–7. ©2002 by American Society for Reproductive Medicine.)

Key Words: Embryo, oocyte, ovarian stimulation, recombinant human FSH, urinary human FSH

Induction of multifollicular growth in assisted reproduction programs is essential for successful treatment. Since pregnancy and live birth rates are correlated with the number of fertilized oocytes (1), IVF procedures have historically used protocols involving administration of gonadotropins to increase the number of oocytes available for eventual embryo transfer.

Ovarian stimulation regimens generally include pituitary desensitization (down-regulation) with a GnRH analogue followed by administration of gonadotropins (2). Pituitary down-regulation with GnRH agonist, which inhibits the mid-cycle LH surge, is one of the most effective ways to induce formation of enough preovulatory follicles (3–5).

Until recently, gonadotropins used for ovarian stimulation have been extracted from the urine of postmenopausal women. Since menopausal gonadotropin (hMG) is of human origin, the source is not consistent and the end product is always contaminated with >95% non-FSH, human proteins, and LH (6). Urinary proteins may negatively affect follicle recruitment and development (7).

The introduction of highly purified urinary FSH, which contained >95% FSH protein content and a negligible amount (0.1 per 1,000 IU of FSH) of LH (8), has substantially addressed the contamination problem. Some reports have indicated that use of highly purified FSH has
resulted in higher pregnancy rates than those obtained with hMG (9–11).

With the advent of recombinant DNA technology, two pure FSH preparations have become available: follitropin-α and follitropin-β. Recombinant human FSH has a specific activity of >10,000 IU/mg protein and lacks LH activity or extraneous human proteins (12–14). Its purity and in vivo bioactivity are thought to confer safety, efficiency, and tolerability advantages over urine-derived FSH (15, 16).

Recent clinical trials have shown that recombinant FSH is effective in terms of number of oocytes retrieved, number of embryos obtained, and total gonadotropin dose needed, without increasing the risk for the ovarian hyperstimulation syndrome (OHSS) (17–19). In addition, recombinant FSH has been shown to be as effective as urinary FSH or hMG (20–24), with or without GnRH agonists. However, in most of these trials, the main end points were the number of oocytes retrieved and embryos obtained, dosage and duration of stimulation, and rates of fertilization, pregnancy, and implantation.

Few trials have investigated the possible difference between recombinant FSH and highly purified urinary FSH in terms of the quality of oocytes and embryos in stimulated cycles. Recent data show that hMG compares favorably to recombinant FSH (25, 26) in terms of oocyte and embryo quality and subsequent pregnancy rates.

We sought to compare the effects of highly purified urinary FSH and recombinant FSH on oocyte and embryo quality and on pregnancy and implantation rates.

MATERIALS AND METHODS

Patient Selection

Two hundred sixty-seven infertile couples were recruited between December 1998 and November 2000. Women 18 to 38 years of age were included if they fulfilled the following criteria: [1] infertility attributable to tubal factor, male factor, or unexplained infertility; [2] serum levels of FSH, LH, and prolactin in the normal range; [3] regular ovulatory menstrual cycles of 25 to 35 days; [4] a normal uterine cavity; [5] no treatment with gonadotropins in the month before study entry; [6] presentation for the first IVF treatment cycle; [7] body mass index ≥18 but ≤26 kg/m²; and [8] willingness to participate in the study and to comply with the procedures.

Patients were excluded if they had gynecologic abnormalities or disease, previous poor response to gonadotropins used for IUI, history of severe OHSS, or current polycystic ovary syndrome or if the male partner had azoospermia or clinical signs of infection detected in semen analysis within 12 months before treatment.

Patients were extensively counseled about the nature of the study and gave written informed consent. The Institutional Review Board of each participating center approved the study.

Study Design

We performed a prospective, open, randomized, parallel-group study at three hospital-affiliated IVF centers in Italy. The study was designed to compare the effectiveness of recombinant FSH (Gonal-F; Serono, Rome, Italy) and highly purified urinary FSH (Fostimon; AMSA, Rome, Italy) administered during a single IVF cycle. Evaluation was based on the number of mature oocytes and on embryo quality as a primary end point of the study.

Fostimon is a new preparation of highly purified urinary FSH obtained by an ion-exchange chromatography column method. It has a specific activity of >6,000 IU/mg protein and purity >90%. This high level of biological potency and purity allows safe administration by intramuscular or subcutaneous routes.

All patients underwent standard pituitary down-regulation with GnRH analogue (triptorelin) (Decapeptyl; Ipsen, Milan, Italy), 3.75 mg i.m. on day 21 of their cycle. Fifteen days later, patients were considered desensitized and gonadotropin administration was begun, provided that ultrasonography showed no follicles ≥10 mm in diameter, endometrial thickness <7 mm, and estradiol serum concentration <50 pg/mL.

After pituitary desensitization, patients were randomized to receive highly purified urinary FSH or recombinant FSH, administered once daily s.c., starting with a fixed dose of 225 IU/d for the first 6 days. Ovarian response was assessed on day 6 by ultrasonography and by measurement of serum estradiol to evaluate whether a change in the dose was required.

Patients with a poor response to gonadotropin treatment were withdrawn from the study. Patients with excessive response were counseled about the risk for OHSS and were advised to interrupt the stimulation cycle or to undergo oocyte retrieval with cryopreservation of any resultant embryos for replacement in the subsequent cycle.

Follicle-stimulating hormone was administered daily until the criteria for triggering final follicular maturation (leading follicle with a mean diameter ≥18 mm and at least two other follicles with a diameter >16 mm) were met. Ovulation was triggered by i.m. administration of 10,000 IU of hCG 12 to 16 hours after the last ultrasonogram that confirmed adequate follicular development.

Oocytes were retrieved 34 to 36 hours after hCG administration. The cumulus–oocyte complex was assessed according to the oocyte maturation score criteria described by Veeck (27). The oocytes were then inseminated in vitro by conventional IVF or ICSI, and the resultant embryos were scored according to the criteria of Veeck (28).

In brief, embryos were scored on the basis of morphologic appearance and fragmentation. Grade 1 embryos had...
equal-sized blastomeres and no fragmentation; grade 2 embryos had equal-sized blastomeres with minor cytoplasmic fragmentation; grade 3 embryos had unequal-sized blastomeres with variable fragmentation; grade 4 embryos had equal- or unequal-sized blastomeres with >10% fragmentation; grade 5 embryos had equal- or unequal-sized blastomeres and >20% fragmentation; and grade 6 embryos had few, small blastomeres and severe fragmentation comprising >50% of the embryo surface (28).

Embryos were transferred on day 3 after oocyte retrieval. No more than three embryos per patient were transferred. Luteal phase support was initiated on the day of oocyte retrieval by using a commercially available progesterone preparation (50 mg/mL i.m.). Surplus embryos were cryopreserved. Clinical pregnancy was confirmed 6 weeks after embryo transfer by ultrasonography.

**Efficacy Measures**

Primary end points were the number of mature oocytes retrieved, embryo quality, and clinical pregnancy and implantation rates. Secondary endpoints were total dose of FSH administered, total number of days of stimulation, serum estradiol level and endometrial thickness on the day of hCG administration, fertilization rate, embryo cleavage rate, live birth and miscarriage rates, cancellation rate, and incidence of moderate or severe OHSS. All end points except the cancellation rate, the incidence of OHSS, and the number of frozen embryos were analyzed statistically.

**Statistical Analysis**

The $t$-test, $\chi^2$ square table of contingency, and analysis of variance were used where appropriate. Statistical significance was established if $P \leq 0.05$.

**RESULTS**

The patients were divided into two groups: One hundred thirty-three received highly purified FSH (urofollitropin), and 134 “controls” received recombinant FSH (follitropin-α). Of the 267 randomized patients, 264 completed the cycle and had oocyte retrieval. Two couples in the urinary FSH group and one couple in the recombinant FSH group (1.5% and 0.7% of patients, respectively) were excluded owing to excessive ovarian response leading to high risk for OHSS.

The two study groups were similar in terms of age, body mass index, duration of stimulation, number of ampules or vials of FSH administered, and estradiol level and endometrial thickness on day of hCG administration (Table 1).

![Table 1](image)

**DISCUSSION**

The recent availability of recombinant FSH has introduced an alternative to urine-derived FSH for ovarian stimulation regimens. Several comparison studies have shown that recombinant FSH is more effective than urinary FSH.
Recombinant FSH contains a higher proportion of the less acidic isoforms (isoelectric point range of 3.5 to 6.1), whereas urinary FSH containing both acidic and mid-acidic isoforms (isoelectric point range of 3.5 to 5.2). It has been suggested that the less acidic isoforms have faster circulatory clearance and, thus, a shorter circulatory half-life (37) than the acidic isoforms (38, 39). A more recent study has shown that the slow clearance of the acidic isoform results in better follicular maturation and estradiol secretion than the less acidic isoform (40). Further investigation into the role of FSH isoforms in the modulation and regulation of follicular growth and maturation is needed.

In our study, the mean number of retrieved oocytes (8.7 ± 3.4 vs. 8.9 ± 4.7) and the number of morphologically mature oocytes (7.4 ± 1.8 vs. 7.7 ± 3.2) did not differ between the urinary FSH group and the recombinant FSH group. Of note, the serum estradiol level on the day of hCG administration was nonsignificantly higher in the urinary FSH group than in the recombinant FSH group (1,891 ± 975.5 pg/mL vs. 1,698.5 ± 864.4 pg/mL). These findings contrast with those of some previous studies (18, 19, 41) but agree with those of Jacob et al. (42), who found a significantly lower estradiol level in the recombinant FSH group than in the urinary FSH (or hMG) group. This observation might be explained by the fact that LH is required for normal steroidogenesis activity during follicular growth while increasing the number of FSH receptors on granulosa cells (43). Alternatively, the negligible amount of LH in highly purified urinary FSH may affect estrogen production (22, 42).

Patients treated with urinary FSH had a statistically higher number of grade 1 embryos than did patients treated with recombinant FSH group (42.1% vs. 33.5%; P<.05), but the number of morphologically mature oocytes was similar in the two groups. The number of grade 2, 3, 4, and 5 embryos was similar in both groups, whereas the number of grade 6 embryos was statistically lower in the urinary FSH group. These differences may reflect the slightly higher

### TABLE 2
Oocyte maturity and fertilization and cleavage rates in patients stimulated with highly purified FSH or recombinant FSH.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Highly purified FSH group</th>
<th>Recombinant FSH group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients with oocyte retrieval</td>
<td>131</td>
<td>133</td>
<td>.878</td>
</tr>
<tr>
<td>No. of retrieved oocytes</td>
<td>1,146</td>
<td>1,197</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>8.7 ± 3.4</td>
<td>8.9 ± 4.7</td>
<td></td>
</tr>
<tr>
<td>No. of morphologically matured oocytes (%)</td>
<td>978 (85.3)</td>
<td>1,029 (86)</td>
<td>.804</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>7.4 ± 1.8</td>
<td>7.7 ± 3.2</td>
<td></td>
</tr>
<tr>
<td>No. of two-pronuclei oocytes (%)</td>
<td>741 (64.6)</td>
<td>788 (65.8)</td>
<td>.766</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>5.7 ± 1.7</td>
<td>5.9 ± 2.1</td>
<td></td>
</tr>
<tr>
<td>Cleaved embryos (%)</td>
<td>589 (79.5)</td>
<td>668 (84.7)</td>
<td>.449</td>
</tr>
</tbody>
</table>

Note: Values with the plus/minus sign are the mean (±SD).


(hMG or highly purified FSH) and that the absence of LH activity in recombinant FSH does not inhibit follicular growth.

Studies have shown that FSH, even in the absence of LH, induces multiple follicular growth as well as meiotically and developmentally competent oocytes (17), although serum concentrations of estradiol remain lower than levels resulting from follicular stimulation with hMG (29–33). However, in agreement with our results, recent studies of urinary FSH or hMG and recombinant FSH had similar results in terms of oocyte and embryo quality and of implantation and pregnancy rates (25, 26, 34).

We aimed to compare highly purified FSH with recombinant FSH to evaluate possible differences in oocyte and embryo quality and in implantation and pregnancy rates. Highly purified FSH proved to be as effective and safe as recombinant FSH for inducing growth of multiple follicles in stimulation regimens. Subcutaneous administration of highly purified FSH had no side effects and was well tolerated, as reported in previous studies (35, 36).

### TABLE 3
Embryo score after stimulation with highly purified FSH or recombinant FSH.

<table>
<thead>
<tr>
<th>Embryo score</th>
<th>Highly purified FSH group</th>
<th>Recombinant FSH group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 (%)</td>
<td>248 (42.1)</td>
<td>224 (33.5)</td>
<td>.05</td>
</tr>
<tr>
<td>Grade 2 (%)</td>
<td>183 (31)</td>
<td>203 (30.4)</td>
<td>.887</td>
</tr>
<tr>
<td>Grade 3 (%)</td>
<td>59 (10)</td>
<td>86 (12.9)</td>
<td>.186</td>
</tr>
<tr>
<td>Grade 4 (%)</td>
<td>40 (6.8)</td>
<td>63 (9.4)</td>
<td>.142</td>
</tr>
<tr>
<td>Grade 5 (%)</td>
<td>29 (5)</td>
<td>35 (5.3)</td>
<td>.910</td>
</tr>
<tr>
<td>Grade 6 (%)</td>
<td>30 (5.1)</td>
<td>57 (8.5)</td>
<td>.05</td>
</tr>
</tbody>
</table>

*The embryos were scored according to the criteria established by Veeck (1988).

pregnancy and implantation rates in patients treated with urinary FSH compared with recombinant FSH (46.5% vs. 36.8% and 22.1% vs. 15.8%, respectively). The slightly lower miscarriage rates and higher live birth rates in the urinary FSH group may indicate that urinary FSH has a better effect on embryo quality.

The rate of pregnancy, implantation, and live birth may not have differed significantly between the groups because of small sample. Assuming that the difference between recombinant FSH and urinary FSH is 5%, at least 1,212 participants for each group would be needed to reach 90% power and an α value of .05. However, our study has a statistical power of 15% to 20%.

Of the factors that affect oocyte quality in stimulated cycles, the most important appear to be patient age, basal FSH concentration, profound suppression of LH during down-regulation, and estradiol concentration per growing follicle. Estradiol and androgens are reported to affect oocyte nuclear maturation and fertilization and may contribute to embryo development (44–47).

Profound suppression of LH during the down-regulation protocols generally used for ovarian stimulation negatively affects treatment outcome (48–50). Recent studies demonstrated that low concentrations of endogenous LH (<3 mIU/mL) in the late follicular phase of an IVF cycle are associated with significantly lower fertilization rates and higher biochemical pregnancy rates. The authors suggested that when using recombinant FSH only, it may be of clinical benefit to add LH in the late follicular phase or to further reduce the dose of GnRH analogue (48, 51).

Conversely, recombinant FSH is reported to be more effective than urinary FSH for ovarian stimulation, even when used in combination with a long-acting GnRH agonist (depot formulation) (20, 29, 52). Loumaye et al. (53) reported that patients with very suppressed serum LH levels respond similarly to those with moderately suppressed LH levels and that about 60% of patients might benefit from a more pronounced pituitary down-regulation, whereas only less than 6% of patients would benefit from exogenous LH administration (53).

Although LH plays an important role during ovarian stimulation (44), excessive LH during the follicular phase has been shown to have a detrimental effect on oocyte quality and thus fertility (54). However, other studies found that an elevated LH level on the day of hCG administration in a low-GnRH analogue protocol does not reduce cycle fecundity (55). These discrepant findings require further investigation. In a recent study, hMG (1:1 FSH/LH) produced comparable results to recombinant FSH when used alone for ovarian stimulation (25, 26, 56).

We conclude that highly purified FSH is as effective as recombinant FSH for ovarian stimulation protocols, thus offering a viable alternative to recombinant FSH.

References


TABLE 4

Clinical outcome of patients after treatment with highly purified FSH or recombinant FSH.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Highly purified FSH group</th>
<th>Recombinant FSH group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients with embryo transfer</td>
<td>131</td>
<td>133</td>
<td>.955</td>
</tr>
<tr>
<td>No. of embryos transferred</td>
<td>380</td>
<td>385</td>
<td>.353</td>
</tr>
<tr>
<td>No. of embryos cryopreserved</td>
<td>98</td>
<td>120</td>
<td>.688</td>
</tr>
<tr>
<td>Average of embryos transferred per patient</td>
<td>2.9</td>
<td>2.9</td>
<td>.360</td>
</tr>
<tr>
<td>No. of clinical pregnancies (%)</td>
<td>61 (46.5)</td>
<td>49 (36.8)</td>
<td>.668</td>
</tr>
<tr>
<td>Multiple pregnancies per clinical pregnancy (%)</td>
<td>18 (29.5)</td>
<td>11 (22.4)</td>
<td>.937</td>
</tr>
<tr>
<td>Twins</td>
<td>13</td>
<td>9</td>
<td>.665</td>
</tr>
<tr>
<td>Triplets</td>
<td>5</td>
<td>2</td>
<td>.946</td>
</tr>
<tr>
<td>Spontaneous abortion rate per clinical pregnancy (%)</td>
<td>9/61 (14.7)</td>
<td>8/49 (16.3)</td>
<td>.099</td>
</tr>
<tr>
<td>Implantation rate per embryo transferred (%)</td>
<td>84/380 (22.1)</td>
<td>62/385 (15.8)</td>
<td>.356</td>
</tr>
<tr>
<td>No. of deliveries per embryo transfer (%)</td>
<td>52 (39.7)</td>
<td>41 (30.8)</td>
<td>.946</td>
</tr>
</tbody>
</table>

* Only viable embryos were cryopreserved when requested by the patients.

* Spontaneous abortion includes one triplet for each group.


